NCT01710644 - Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions

Pancreatic InsufficiencyCystic FibrosisDigestive System DiseasesLung DiseasesRespiratory Tract Diseases

Interventions

DRUG

Burlulipase

Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days

DRUG

Placebo (Caramel in sterile water)

Placebo will be taken with meals and snacks for 5 to 7 days

Trial Locations (9)

Penn State Milton S. Hershey Medical Center, Hershey

West Virginia University Research Corporation, Morgantown

Nemours Children's Clinic, Jacksonville

Nemours Children's Clinic, Pensacola

University Hospitals Case Medical Center, Cleveland

Cincinnati Children's Hospital Medical Center, Cincinnati

The Children's Medical Center of Dayton, Dayton

The University of Iowa, Iowa City

Via Cristi Hospitals Wichita, Inc., Wichita